CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. Companies in the space not only recognize the importance of remaining cognizant of the change in demand from consumers but are working hard to create products and services tailored to the specific qualifications of each customer. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.
Premier Health Group, Inc (OTC:PHGRF) (CSE:PHGI);'s subsidiary, HealthVue is dead-set on developing proprietary technology to deliver healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally. This is in line with the latest trend that's been growing within healthcare targeting new connected technology.
Premier Health Group, Inc (OTC:PHGRF) (CSE:PHGI) announced earlier this month that, as part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding LOI to acquire a Vancouver, British Columbia based pharmacy. According to reports, the Company expects the acquisition of the pharmacy to close in or about Q1-19. Additionally, the Company has made it a priority to work with telehealth tech experts and providers to further develop its immensely successful HealthVue app, which allows patients to access primary care physicians through the use of any smartphone or tablet.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-basedpatient centric model," said Dr. Essam Hamza, CEO of Premier. "Premier has engaged with patients, pharmacies and technology providers to not only introduce pharmacy services as a component of our comprehensive telemedicine app, but also to explore and implement efficiencies in fill and fulfillment."
Aevi Genomic Medicine Inc saw its shares jump 7.24% in midday trading on Thursday, with shares going for $1.12 per share, capitalizing onmomentum gained from the Company’s quarterly earnings report back in November. According to said results, the Company announced that it had completed enrollment for the ASCEND trial, a genetically-guided Phase 2 study of AEVI-001, a novel, non-stimulant therapy in pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD).
"It has been a productive quarter for Aevi," said Mike Cola, Chief Executive Officer of the Company. "We were able to successfully utilize our ATM facility to bring in approximately $5.0 million in the capital which has allowed us to move forward in our programs. Completing enrollment in Parts A and B of the ASCEND trial was an important milestone for the Company, and we look forward to sharing data from the trial in January 2019. In addition to progress with AEVI-001, we are developing AEVI-004 as a follow-on to AEVI-001 in ADHD and potentially other adjacent neuropsychiatric indications and are making progress in our preclinical work on AEVI-005."
Aurinia Pharmaceuticals Inc., (AUPH) announced at the end of November that it had entered into an Open Market Sale Agreement with Jeffries LLC pursuant to which the Company may from time to time sell, through at-the-market offerings with Jefferies acting as aisles agent or directly to Jeffries acting as principal, such common shares in the capital of the Company as would have an aggregate offering price of up to $30 million.
In addition to this announcement, stated in an official press release from the Company, Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada, and with the US Securities and Exchange Commission.
CV Sciences, Inc (CVSI) announced that it would be participating as a presenter at the Biotech Showcase™ investor and networking conference on Monday, January 7, 2019. Given that it will be the eleventh year that the Biotech event has occurred, the conference will undoubtedly provide attendees with opportunities to network with investors, sector analysts, bankers and industry professionals.
"Biotech Showcase™ boasts a strong attendance of international investors, many of whom will be hearing our business model and investment opportunity for the first time," stated Chief Executive Officer Joseph Dowling. "The event is considered a critical early benchmark for investors in the new year that want to follow high growth opportunities in the small-cap biotech sector and we are excited to be utilizing this platform to communicate our recent strong quarterly growth announcement that included record sales, record gross profit and record GAAP Net Income."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)